The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1757
June 22, 2026
View Complete Issue         Table of Contents 2019 
Tradipitant (Nereus) for Motion Sickness
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tradipitant (Nereus) for Motion Sickness
June 22, 2026 (Issue: 1757)
The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant (Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tradipitant (Nereus) for Motion Sickness
Article code: 1757a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.